Premium
Chromosomal abnormalities in Philadelphia chromosome‐negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome‐positive chronic myelogenous leukemia in chronic phase
Author(s) -
Medina Jorge,
Kantarjian Hagop,
Talpaz Moshe,
O'Brien Susan,
GarciaManero Guillermo,
Giles Francis,
Rios Mary Beth,
Hayes Kimberly,
Cortes Jorge
Publication year - 2003
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.11729
Subject(s) - medicine , chronic myelogenous leukemia , imatinib mesylate , philadelphia chromosome , imatinib , trisomy 8 , gastroenterology , trisomy , cancer , chromosome abnormality , pathology , leukemia , cytogenetics , chromosome , karyotype , chromosomal translocation , biology , genetics , myeloid leukemia , gene
Abstract BACKGROUND Anecdotal cases of chromosomal abnormalities in Philadelphia chromosome (Ph)‐negative metaphases have been reported in patients with chronic myelogenous leukemia (CML) in the chronic phase during treatment with interferon and, more recently, with imatinib. This phenomenon is different from true clonal evolution in that the additional cytogenetic abnormality occurs in Ph‐negative cells. METHODS The authors analyzed their experience with 342 patients with CML in chronic phase treated with imatinib to investigate the frequency and significance of this event. RESULTS After a median follow‐up of 30 months (range, 16–35 months), 21 patients (6%; 95% confidence interval, 0.04, 0.09) developed 25 chromosomal abnormalities in Ph‐negative cells. Thirteen (54%) of these abnormalities were seen in 2 or more metaphases. The median time from the start of treatment with imatinib to the appearance of the abnormalities was 6 months (range, 3–22 months). The most common cytogenetic abnormality detected was trisomy 8 (33%). Twenty of 21 patients (95%) achieved a major (Ph < 35%) cytogenetic response (complete cytogenetic response in 13–62%). After a median follow‐up of 22 months (range, 4–33 months), all 21 patients were alive, 20 of them in chronic phase and in complete hematologic response. None of the patients showed features of myelodysplasia. CONCLUSIONS Cytogenetic abnormalities occur in Ph‐negative cells in a fraction of patients with CML in chronic phase treated with imatinib. With a short follow‐up, no clear clinical consequences can be identified. Cancer 2003. © 2003 American Cancer Society.